替罗非班对急性冠脉综合征患者血小板CD40L及血清MMP-9水平的影响  

Effect of tirofiban on the expression of platelet membrane-bound CD40 Ligand and MMP-9in plasma in patients with acute coronary syndrome

作　　者：刘晓霞[1] 李萌[1] 李学奇[1] 

机构地区：[1]哈尔滨医科大学附属四院,黑龙江哈尔滨150001

出　　处：《中国实验诊断学》2010年第8期1209-1211,共3页Chinese Journal of Laboratory Diagnosis

摘　　要：目的观察盐酸替罗非班对急性冠脉综合征(ACS)患者血小板CD40L表达、血清MMP-9水平的影响。方法 ACS患者60例,随机分为试验组与对照组,应用流式细胞术及明胶酶谱法分别检测药物治疗前及48小时后血小板CD40L及血清MMP-9水平。结果试验组血小板CD40L及血清MMP-9升高水平较对照组低(P<0.05)。结论替罗非班可以减弱ACS患者血小板CD40L、血清MMP-9表达,对预防ACS患者进一步的心脏缺血事件有积极作用。Objective To observe the effect of tirofiban to the expression of platelet membrane-bound CD40L and MMP-9 in plasma in vivo in patients with acute coronary. Methods 60ACS patients were randomly divided into control group and tirofiban treatment group, all patients received drug treatment after diagnosis, the platelet membrane-bound CD40L were determined by flow cytometry and plasma MMP-9 levels were measured by gelatin zymograph. Results The in-crease of CD40L and MMP-9 in tirofiban treatment group was less than that in controlled group. Conclusion Conclusions Tirofiban can reduce the expression of platelet mem- brane-bound CD40L and MMP-9 in plasma in patients with ACS; Tirofiban took an active part in preventing the coronary ischemic event .

关 键 词：急性冠脉综合征 血小板GPⅡb/Ⅲa受体拮抗剂 基质金属蛋白酶 血小板CD40L 

分 类 号：R541.4[医药卫生—心血管疾病]